Luke Evnin, a director at Werewolf Therapeutics, Inc., recently completed three distinct transactions involving the sale of the company's common stock. In total, Mr. Evnin disposed of 139,803 shares, bringing the value of these sales to an estimated $63,628.
These divestitures were executed over a period spanning June 1 through June 3, 2026. The per-share prices across these multiple trades ranged from $0.42 to $0.495. It is important to note that all reported sales adhered to the terms of a Rule 10b5-1 trading plan, which Mr. Evnin had originally established on March 26, 2026.
Details of the Transactions
The sales were structured across three specific dates, each detailing unique transaction parameters:
- June 1, 2026: Mr. Evnin sold a quantity of 80,459 shares. These shares were transacted at a weighted average price of $0.47 per share, with individual transaction prices observed between $0.45 and $0.495.
- June 2, 2026: A further sale involved 29,595 shares. The weighted average price for this day was set at $0.45, while the range of individual transaction prices spanned from $0.4304 to $0.46.
- June 3, 2026: The final reported sale accounted for 29,749 shares. These were sold with a weighted average price of $0.42 per share, and the specific transaction prices fell between $0.42 and $0.4367.
Contextual Analysis of Stock Valuation
The timing of these sales occurred when Werewolf Therapeutics' stock was trading near its 52-week low, specifically just 4% above that historical floor of $0.40. Market analysis suggests differing viewpoints on the company's valuation at current levels. According to InvestingPro analysis, HOWL currently appears undervalued.
Furthermore, the company has experienced a notable decline, having fallen nearly 14% over the past week alone. On its balance sheet, Werewolf Therapeutics is reported to maintain more cash than it carries in debt, though the organization continues to face challenges related to profitability.
Beneficial Ownership and Holdings
The shares that were sold did not pass directly through Mr. Evnin's personal accounts but were instead held indirectly by various affiliated entities. These included:
- MPM Asset Management LLC
- MPM BioVentures 2014, L.P.
- MPM BioVentures 2014(B), L.P.
- MPM Asset Management Investors BV2014 LLC
- MPM Oncology Innovations Fund, L.P.
Mr. Evnin holds a role as a member, Managing Director, or manager of the general partners or managers for these listed entities. He explicitly disclaimed beneficial ownership of the securities except to the extent of his own pecuniary interest.
Following these recent transactions, Mr. Evnin's reported indirect holdings in Werewolf Therapeutics common stock amount to 482,776 shares.
(Note: The provided data includes additional market metrics and analysis tools for HOWL, such as price charts and valuation reports, which are referenced here only for context of the company's trading activity.)